Enveric nominates psilocin prodrug EB-373 as lead candidate for anxiety disorders
Oct. 25, 2022
Enveric Biosciences Inc. has nominated EB-373 as the lead development candidate to emerge from its EVM201 program. EB-373 is under development for the treatment of anxiety disorders.